AR111241A1 - Compuestos de imidazo-piperidina fusionada como inhibidores de jak - Google Patents
Compuestos de imidazo-piperidina fusionada como inhibidores de jakInfo
- Publication number
- AR111241A1 AR111241A1 ARP180100542A ARP180100542A AR111241A1 AR 111241 A1 AR111241 A1 AR 111241A1 AR P180100542 A ARP180100542 A AR P180100542A AR P180100542 A ARP180100542 A AR P180100542A AR 111241 A1 AR111241 A1 AR 111241A1
- Authority
- AR
- Argentina
- Prior art keywords
- 3alkyl
- nitrogen atom
- optionally substituted
- membered heterocyclyl
- taken together
- Prior art date
Links
- AIAJYBLPGVBVSS-UHFFFAOYSA-N 4,5,6,7-tetrahydro-1h-imidazo[4,5-b]pyridine Chemical class C1CCNC2=C1NC=N2 AIAJYBLPGVBVSS-UHFFFAOYSA-N 0.000 title 1
- 229940122245 Janus kinase inhibitor Drugs 0.000 title 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 17
- 229910052757 nitrogen Inorganic materials 0.000 abstract 14
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 13
- 125000000623 heterocyclic group Chemical group 0.000 abstract 12
- 150000001875 compounds Chemical class 0.000 abstract 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 150000002431 hydrogen Chemical group 0.000 abstract 2
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- NFGODEMQGQNUKK-UHFFFAOYSA-M [6-(diethylamino)-9-(2-octadecoxycarbonylphenyl)xanthen-3-ylidene]-diethylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCCOC(=O)C1=CC=CC=C1C1=C2C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C21 NFGODEMQGQNUKK-UHFFFAOYSA-M 0.000 abstract 1
- KCNKJCHARANTIP-SNAWJCMRSA-N allyl-{4-[3-(4-bromo-phenyl)-benzofuran-6-yloxy]-but-2-enyl}-methyl-amine Chemical compound C=1OC2=CC(OC/C=C/CN(CC=C)C)=CC=C2C=1C1=CC=C(Br)C=C1 KCNKJCHARANTIP-SNAWJCMRSA-N 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 125000002757 morpholinyl group Chemical group 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 229910052760 oxygen Chemical group 0.000 abstract 1
- 239000001301 oxygen Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762469073P | 2017-03-09 | 2017-03-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR111241A1 true AR111241A1 (es) | 2019-06-19 |
Family
ID=61683956
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180100542A AR111241A1 (es) | 2017-03-09 | 2018-03-08 | Compuestos de imidazo-piperidina fusionada como inhibidores de jak |
| ARP180100543A AR111242A1 (es) | 2017-03-09 | 2018-03-08 | Compuestos de imidazo-piperidina fusionada que contienen una amida heterocíclica de 4 miembros como inhibidores de jak |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180100543A AR111242A1 (es) | 2017-03-09 | 2018-03-08 | Compuestos de imidazo-piperidina fusionada que contienen una amida heterocíclica de 4 miembros como inhibidores de jak |
Country Status (20)
| Country | Link |
|---|---|
| US (10) | US10208040B2 (enExample) |
| EP (2) | EP3592743A1 (enExample) |
| JP (2) | JP6974487B2 (enExample) |
| KR (2) | KR102526764B1 (enExample) |
| CN (2) | CN110461839B (enExample) |
| AR (2) | AR111241A1 (enExample) |
| AU (2) | AU2018231032B2 (enExample) |
| BR (2) | BR112019018648A2 (enExample) |
| CA (1) | CA2997772A1 (enExample) |
| DK (1) | DK3592742T3 (enExample) |
| EA (2) | EA037261B1 (enExample) |
| ES (1) | ES2882186T3 (enExample) |
| IL (2) | IL268689B2 (enExample) |
| MX (2) | MX388750B (enExample) |
| PH (2) | PH12019501941A1 (enExample) |
| PT (1) | PT3592742T (enExample) |
| SG (2) | SG11201907840RA (enExample) |
| TW (2) | TWI754019B (enExample) |
| WO (2) | WO2018165395A1 (enExample) |
| ZA (2) | ZA201905585B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI710560B (zh) | 2015-11-03 | 2020-11-21 | 美商施萬生物製藥研發Ｉｐ有限責任公司 | 用於治療呼吸疾病之jak激酶抑制劑化合物 |
| EP3831830A1 (en) * | 2015-11-03 | 2021-06-09 | Topivert Pharma Limited | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors |
| TWI754019B (zh) * | 2017-03-09 | 2022-02-01 | 美商施萬生物製藥研發 Ip有限責任公司 | 含有4員雜環醯胺之jak抑制劑 |
| AR111495A1 (es) | 2017-05-01 | 2019-07-17 | Theravance Biopharma R&D Ip Llc | Compuestos de imidazo-piperidina fusionada como inhibidores de jak |
| AU2018261588A1 (en) | 2017-05-01 | 2019-10-31 | Theravance Biopharma R&D Ip, Llc | Methods of treatment using a JAK inhibitor compound |
| DK3837258T3 (da) * | 2018-09-04 | 2024-07-22 | Theravance Biopharma R&D Ip Llc | Dimethyl amino azetidine amides as jak inhibitors |
| BR112021004087A2 (pt) | 2018-09-04 | 2021-05-25 | Theravance Biopharma R&D Ip, Llc | processo para preparar inibidores de jak e seus intermediários |
| BR112021004063A2 (pt) | 2018-09-04 | 2021-05-25 | Theravance Biopharma R&D Ip, Llc | amidas heterocíclicas com 5 a 7 membros como inibidores de jak |
| EP3853229A1 (en) | 2018-10-29 | 2021-07-28 | Theravance Biopharma R&D IP, LLC | 2-azabicyclo hexane compound as jak inhibitor |
| KR102873783B1 (ko) | 2019-02-25 | 2025-10-21 | 메디노 파마슈티컬 테크놀로지 (주하이) 컴퍼니 리미티드 | Jak 억제제 화합물 및 그 사용 |
| US12698289B2 (en) | 2019-02-25 | 2026-08-04 | Henan Medinno Pharmaceutical Technology Co., Ltd. | Solid forms of pharmaceutically acceptable salts of (S)-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-4,6-dihydropyrrolo[3,4-d]imidazol-5(1H)-yl)(3-hydroxypyrrolidin-1-yl)methanone as JAK inhibitors |
| UA130579C2 (uk) | 2019-03-05 | 2026-03-25 | Інсайт Корпорейшн | Інгібітори шляхів jak1 для лікування хронічної дисфункції алотрансплантата легень |
| CN114901659A (zh) * | 2019-11-26 | 2022-08-12 | 施万生物制药研发Ip有限责任公司 | 作为jak抑制剂的稠合嘧啶吡啶酮化合物 |
| JP7580136B2 (ja) * | 2019-12-30 | 2024-11-11 | 路良 | Ｊａｋ阻害剤化合物及びその使用 |
| KR20220149585A (ko) | 2020-03-02 | 2022-11-08 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | Jak 억제제 화합물의 결정성 수화물 |
| EP3944859A1 (en) * | 2020-07-30 | 2022-02-02 | Assistance Publique Hôpitaux de Paris | Method for treating immune toxicities induced by immune checkpoint inhibitors |
| WO2022178215A1 (en) * | 2021-02-19 | 2022-08-25 | Theravance Biopharma R&D Ip, Llc | Amino amide tetrahydro imidazo pyridines as jak inhibitors |
| TW202317550A (zh) * | 2021-06-25 | 2023-05-01 | 美商施萬生物製藥研發 Ip有限責任公司 | 作為jak抑制劑之咪唑吲唑化合物 |
| CN118401508A (zh) * | 2021-12-17 | 2024-07-26 | 株式会社大熊制药 | (2R,3S)-2-(3-(4,5-二氯-1H-苯并[d]咪唑-1-基)丙基)哌啶-3-醇的新酸加成盐及晶形 |
| CN117658852B (zh) * | 2023-11-15 | 2026-03-24 | 西北工业大学 | 取代苯氧乙酰肼类化合物及其制备方法和作为stat3的抗炎抑制剂的应用 |
| WO2025157904A1 (en) * | 2024-01-24 | 2025-07-31 | Kiox Pharmaceuticals Aps | Inhalable formulations of ruxolitinib, methods of manufacture and uses thereof |
| CN118903009B (zh) * | 2024-10-11 | 2025-01-21 | 江苏长泰药业股份有限公司 | 一种调节呼吸道微生态的丙酮酸钠气雾剂及其制备方法和应用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI262914B (en) | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
| US7872014B2 (en) | 2003-07-23 | 2011-01-18 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
| US20050090529A1 (en) | 2003-07-31 | 2005-04-28 | Pfizer Inc | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
| US7884109B2 (en) | 2005-04-05 | 2011-02-08 | Wyeth Llc | Purine and imidazopyridine derivatives for immunosuppression |
| US8648069B2 (en) | 2007-06-08 | 2014-02-11 | Abbvie Inc. | 5-substituted indazoles as kinase inhibitors |
| JP2010111624A (ja) | 2008-11-06 | 2010-05-20 | Shionogi & Co Ltd | Ｔｔｋ阻害作用を有するインダゾール誘導体 |
| CA2756989A1 (en) | 2009-04-03 | 2010-10-07 | Douglas Burdi | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
| SMT201700581T1 (it) | 2009-12-21 | 2018-01-11 | Samumed Llc | 1h-pirazolo[3,4-b]piridine e loro usi terapeutici |
| EP2338888A1 (en) | 2009-12-24 | 2011-06-29 | Almirall, S.A. | Imidazopyridine derivatives as JAK inhibitors |
| US8575336B2 (en) * | 2011-07-27 | 2013-11-05 | Pfizer Limited | Indazoles |
| EP2771340B1 (en) | 2011-10-25 | 2016-04-13 | Sanofi | 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| LT3077395T (lt) | 2013-12-05 | 2018-02-12 | Pfizer Inc. | Pirolo[2,3-d]pirimidinilo, pirolo[2,3-b]pirazinilo ir pirolo[2,3-d]piridinilo akrilamidai |
| PE20161475A1 (es) | 2014-05-14 | 2017-01-08 | Pfizer | Pirazolopiridinas y pirazolopirimidinas |
| WO2016026078A1 (en) | 2014-08-19 | 2016-02-25 | Changzhou Jiekai Pharmatech Co., Ltd. | Heterocyclic compounds as erk inhibitors |
| KR101663277B1 (ko) | 2015-03-30 | 2016-10-06 | 주식회사 녹십자 | TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물 |
| EP3831830A1 (en) * | 2015-11-03 | 2021-06-09 | Topivert Pharma Limited | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors |
| DK3712152T3 (da) | 2015-11-03 | 2021-03-22 | Topivert Pharma Ltd | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridin og 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepinderivater som janus kinase-inhibitorer |
| TWI710560B (zh) | 2015-11-03 | 2020-11-21 | 美商施萬生物製藥研發Ｉｐ有限責任公司 | 用於治療呼吸疾病之jak激酶抑制劑化合物 |
| TWI754019B (zh) * | 2017-03-09 | 2022-02-01 | 美商施萬生物製藥研發 Ip有限責任公司 | 含有4員雜環醯胺之jak抑制劑 |
| EP3619208B1 (en) | 2017-05-01 | 2023-06-07 | Theravance Biopharma R&D IP, LLC | Crystalline forms of a jak inhibitor compound |
| AR111495A1 (es) | 2017-05-01 | 2019-07-17 | Theravance Biopharma R&D Ip Llc | Compuestos de imidazo-piperidina fusionada como inhibidores de jak |
| AU2018261588A1 (en) | 2017-05-01 | 2019-10-31 | Theravance Biopharma R&D Ip, Llc | Methods of treatment using a JAK inhibitor compound |
| KR102032418B1 (ko) | 2017-06-15 | 2019-10-16 | 한국화학연구원 | 접합 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물 |
| DK3837258T3 (da) | 2018-09-04 | 2024-07-22 | Theravance Biopharma R&D Ip Llc | Dimethyl amino azetidine amides as jak inhibitors |
| BR112021004063A2 (pt) | 2018-09-04 | 2021-05-25 | Theravance Biopharma R&D Ip, Llc | amidas heterocíclicas com 5 a 7 membros como inibidores de jak |
| BR112021004087A2 (pt) | 2018-09-04 | 2021-05-25 | Theravance Biopharma R&D Ip, Llc | processo para preparar inibidores de jak e seus intermediários |
-
2018
- 2018-03-08 TW TW107107939A patent/TWI754019B/zh not_active IP Right Cessation
- 2018-03-08 EP EP18712398.9A patent/EP3592743A1/en not_active Withdrawn
- 2018-03-08 WO PCT/US2018/021492 patent/WO2018165395A1/en not_active Ceased
- 2018-03-08 US US15/915,434 patent/US10208040B2/en active Active
- 2018-03-08 CN CN201880017046.0A patent/CN110461839B/zh active Active
- 2018-03-08 SG SG11201907840RA patent/SG11201907840RA/en unknown
- 2018-03-08 CA CA2997772A patent/CA2997772A1/en active Pending
- 2018-03-08 MX MX2019010541A patent/MX388750B/es unknown
- 2018-03-08 TW TW107107936A patent/TWI779016B/zh not_active IP Right Cessation
- 2018-03-08 BR BR112019018648-4A patent/BR112019018648A2/pt not_active IP Right Cessation
- 2018-03-08 AR ARP180100542A patent/AR111241A1/es not_active Application Discontinuation
- 2018-03-08 AR ARP180100543A patent/AR111242A1/es unknown
- 2018-03-08 MX MX2019010539A patent/MX388749B/es unknown
- 2018-03-08 DK DK18711796.5T patent/DK3592742T3/da active
- 2018-03-08 JP JP2019548449A patent/JP6974487B2/ja active Active
- 2018-03-08 BR BR112019018649A patent/BR112019018649A2/pt not_active IP Right Cessation
- 2018-03-08 WO PCT/US2018/021489 patent/WO2018165392A1/en not_active Ceased
- 2018-03-08 PT PT187117965T patent/PT3592742T/pt unknown
- 2018-03-08 KR KR1020197029560A patent/KR102526764B1/ko active Active
- 2018-03-08 CN CN201880016693.XA patent/CN110382498B/zh not_active Expired - Fee Related
- 2018-03-08 AU AU2018231032A patent/AU2018231032B2/en not_active Ceased
- 2018-03-08 KR KR1020197029543A patent/KR102533646B1/ko active Active
- 2018-03-08 AU AU2018231035A patent/AU2018231035B2/en not_active Ceased
- 2018-03-08 EA EA201992126A patent/EA037261B1/ru not_active IP Right Cessation
- 2018-03-08 SG SG11201907544VA patent/SG11201907544VA/en unknown
- 2018-03-08 JP JP2019548369A patent/JP7134990B2/ja not_active Expired - Fee Related
- 2018-03-08 EP EP18711796.5A patent/EP3592742B1/en active Active
- 2018-03-08 ES ES18711796T patent/ES2882186T3/es active Active
- 2018-03-08 US US15/915,418 patent/US10196393B2/en active Active
- 2018-03-08 EA EA201992128A patent/EA037748B1/ru unknown
- 2018-12-17 US US16/222,647 patent/US10392386B2/en active Active
- 2018-12-19 US US16/225,473 patent/US10519153B2/en active Active
-
2019
- 2019-07-15 US US16/511,410 patent/US10550118B2/en active Active
- 2019-08-13 IL IL268689A patent/IL268689B2/en unknown
- 2019-08-13 IL IL268679A patent/IL268679B/en unknown
- 2019-08-22 PH PH12019501941A patent/PH12019501941A1/en unknown
- 2019-08-23 ZA ZA2019/05585A patent/ZA201905585B/en unknown
- 2019-08-26 ZA ZA2019/05618A patent/ZA201905618B/en unknown
- 2019-08-29 PH PH12019501985A patent/PH12019501985A1/en unknown
- 2019-11-11 US US16/679,676 patent/US11254669B2/en not_active Expired - Fee Related
- 2019-12-03 US US16/701,426 patent/US10954237B2/en active Active
-
2021
- 2021-02-12 US US17/248,907 patent/US11453668B2/en active Active
-
2022
- 2022-01-14 US US17/576,089 patent/US11667637B2/en active Active
- 2022-08-10 US US17/885,475 patent/US11878977B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR111242A1 (es) | Compuestos de imidazo-piperidina fusionada que contienen una amida heterocíclica de 4 miembros como inhibidores de jak | |
| AR098721A1 (es) | Inhibidores de biarilo de tirosina quinasa de bruton | |
| AR111776A1 (es) | Heteroarilos inhibidores de las proteínas ras mutantes de g12c | |
| AR116666A1 (es) | Compuestos heterocíclicos | |
| AR104025A1 (es) | Carbamatos de piperazina como moduladores de magl y/o abhd6, procesos para su preparación y composiciones farmacéuticas | |
| AR096643A1 (es) | Procedimiento de síntesis para la preparación de análogos macrocíclicos c1-ceto de halicondrina b e intermediarios útiles en la misma incluyendo intermediarios que contienen grupos -so₂-(p-tolilo) | |
| AR113888A1 (es) | Derivados de indol macrocíclicos sustituidos | |
| AR098492A1 (es) | Derivados de purina | |
| EA202190196A1 (ru) | Новые гетероциклические производные, применимые в качестве ингибиторов shp2 | |
| AR109905A1 (es) | Pirrolidinas sustituidas como moduladores de cftr | |
| AR087901A1 (es) | Derivados dihidroquinolina-2-ona como inhibidores de la aldosterona sintasa y procedimiento para su obtencion | |
| AR110089A1 (es) | Inhibidores de magl | |
| AR089807A1 (es) | Compuestos de imidazopirrolidinona | |
| AR110988A1 (es) | Compuestos de azetidina como moduladores de gpr119 para el tratamiento de la diabetes, la obesidad, la dislipidemia y trastornos relacionados | |
| CU24448B1 (es) | Compuestos de indazol sustituidos y compuestos intermediarios para la preparación de los mismos | |
| AR092742A1 (es) | Piridinonas antifibroticas | |
| AR100886A1 (es) | 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas | |
| AR099890A1 (es) | Inhibidores de histona demetilasas | |
| AR091261A1 (es) | Derivados de alcoholes 1-fenil-2-piridinilalquilicos como inhibidores de la fosfodiesterasa | |
| AR110282A1 (es) | Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1 | |
| AR098909A1 (es) | Compuesto heterocíclico | |
| AR113887A1 (es) | Derivados de indol macrocíclicos sustituidos con cloro | |
| AR113933A1 (es) | Triazolobenzazepinas como antagonistas del receptor v1a de la vasopresina | |
| PE20211769A1 (es) | Compuestos heteroaromaticos como inhibidores de vanina | |
| AR121913A1 (es) | Compuestos terapéuticos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |